BioInvent: New RECIST Context to BI-1808 Data - Redeye
BioInvent published its ESMO 2026 abstract for BI-1808 plus pembrolizumab in platinum-resistant ovarian cancer this weekend. The standard RECIST together with the iRECIST data was published for the mPFS. However, no new data was published.
ANNONS
BioInvent published its ESMO 2026 abstract for BI-1808 plus pembrolizumab in platinum-resistant ovarian cancer this weekend. The standard RECIST together with the iRECIST data was published for the mPFS. However, no new data was published.